The LUMEOS study is now enrolling eligible participants globally in a research study to determine if an investigational gene therapy is effective in people with X-Linked Retinitis Pigmentosa.

Retinitis pigmentosa (RP) includes several genetic conditions that cause vision loss. RP usually appears in childhood or early adulthood and gets worse over time. In some cases, RP is X-linked (XL, meaning that it occurs on the X chromosome) and involves a variant of the RPGR gene (Retinitis Pigmentosa GTPase Regulator).

There are currently no approved treatments available for this type of RP known as XLRP-RPGR. Researchers continue to test possible treatments for this condition.

Who can take part in the LUMEOS study?

The LUMEOS study is looking for males and females who:

  • Are 3 years of age or older and able to perform all of the required study assessments
  • Have XLRP caused by a variant in the RPGR gene
    • Genetic testing is done as part of this study, prior to receiving the investigational gene therapy
    • Or if genetic testing has been completed previously, those results may be used if done by a sponsor-approved laboratory

This is not a complete list of study requirements. The study doctor will review all study related details and determine if you are eligible to participate.

Thank you for considering taking part in the LUMEOS study.